Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
17 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism” 64 citations
,
January 1985 in “Clinical endocrinology” A combination of desogestrel and ethinyl oestradiol effectively reduces hair growth in hirsute women.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
November 2024 in “Gynecological Endocrinology” The article's findings are uncertain and should be viewed with caution.
December 2024 in “Frontiers in Neurology” Testosterone with finasteride improved muscle and bone health in men with spinal cord injury.
January 2004 in “Zhongguo yiyuan yongyao pingjia yu fenxi” Using tamsulosin with finasteride is the most effective and reduces surgery risk for BPH.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
15 citations
,
April 1997 in “Muscle & Nerve” 5 citations
,
April 1997 in “Muscle & Nerve” 1 citations
,
November 2006 in “Medicina de Familia SEMERGEN”
16 citations
,
December 2012 in “Bioinformation” Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
10 citations
,
April 2006 in “Seminars in Reproductive Medicine” Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.
September 2003 in “Reactions Weekly”
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
September 2002 in “Research Repository (Kingston University London)” Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
May 2024 in “The journal of sexual medicine” Finasteride treatment may cause erectile dysfunction, but stopping it reverses these effects.
19 citations
,
June 2010 in “Journal of acupuncture and meridian studies” A plant extract was found to effectively block an enzyme related to male hormone-related diseases.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
2 citations
,
April 2018 in “Current Pharmaceutical Analysis” A new, simple, and accurate method was created to measure finasteride in tablets.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.